Adjunctive benzodiazepines in depression: A clinical dilemma with no recent answers from research

Riccardo De Giorgi, Angharad de Cates

Research output: Contribution to journalArticlepeer-review

Abstract

Comorbid anxiety symptoms are common in depression, and adding benzodiazepines to antidepressant treatment may seem a rational clinical solution. Benzodiazepines also have potential to reduce the initial anxiety that may be caused by early antidepressant treatment (owing to their inhibitory effect via GABAA receptor binding). This month's Cochrane Corner review examines the evidence behind combination treatment versus antidepressants alone in major depressive disorder, in terms of both the clinical and neuroscientific context. The review provides evidence that, in the first 4 weeks of treatment, additional medication with a benzodiazepine may lead to greater improvements than antidepressant alone on ratings of severity, response rates and remission rates for depression, but not on measures of anxiety.

Original languageEnglish
Pages (from-to)321-326
Number of pages6
JournalBJPsych Advances
Volume26
Issue number6
DOIs
Publication statusPublished - 1 Nov 2020

Bibliographical note

Publisher Copyright:
Copyright © The Authors 2020.

Keywords

  • anti-anxiety drugs
  • antidepressants
  • Depressive disorders

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Adjunctive benzodiazepines in depression: A clinical dilemma with no recent answers from research'. Together they form a unique fingerprint.

Cite this